270 related articles for article (PubMed ID: 27919749)
1. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.
Gandoglia I; Ivaldi F; Carrega P; Armentani E; Ferlazzo G; Mancardi G; Kerlero de Rosbo N; Uccelli A; Laroni A
Immunol Lett; 2017 Jan; 181():109-115. PubMed ID: 27919749
[TBL] [Abstract][Full Text] [Related]
2. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
Gross CC; Schulte-Mecklenbeck A; Rünzi A; Kuhlmann T; Posevitz-Fejfár A; Schwab N; Schneider-Hohendorf T; Herich S; Held K; Konjević M; Hartwig M; Dornmair K; Hohlfeld R; Ziemssen T; Klotz L; Meuth SG; Wiendl H
Proc Natl Acad Sci U S A; 2016 May; 113(21):E2973-82. PubMed ID: 27162345
[TBL] [Abstract][Full Text] [Related]
3. Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.
Cobo-Calvo Á; Figueras A; Bau L; Matas E; Mañé Martínez MA; León I; Majòs C; Romero-Pinel L; Martínez-Yélamos S
Clin Immunol; 2016 Oct; 171():18-24. PubMed ID: 27496090
[TBL] [Abstract][Full Text] [Related]
4. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.
Mirjačić Martinović KM; Babović NLj; Džodić RR; Jurišić VB; Tanić NT; Konjević GM
Melanoma Res; 2014 Aug; 24(4):295-304. PubMed ID: 24769842
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.
Fregni G; Messaoudene M; Fourmentraux-Neves E; Mazouz-Dorval S; Chanal J; Maubec E; Marinho E; Scheer-Senyarich I; Cremer I; Avril MF; Caignard A
PLoS One; 2013; 8(10):e76928. PubMed ID: 24204708
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
Jilek S; Mathias A; Canales M; Lysandropoulos A; Pantaleo G; Schluep M; Du Pasquier RA
Mult Scler; 2014 Jun; 20(7):837-42. PubMed ID: 24258149
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.
Carrega P; Pezzino G; Queirolo P; Bonaccorsi I; Falco M; Vita G; Pende D; Misefari A; Moretta A; Mingari MC; Moretta L; Ferlazzo G
PLoS One; 2009 Dec; 4(12):e8132. PubMed ID: 19997637
[TBL] [Abstract][Full Text] [Related]
9. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions.
Morgado S; Sanchez-Correa B; Casado JG; Duran E; Gayoso I; Labella F; Solana R; Tarazona R
J Innate Immun; 2011; 3(4):365-73. PubMed ID: 21576932
[TBL] [Abstract][Full Text] [Related]
10. VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.
White J; Krishnamoorthy S; Gupta D; Lancelot M; Moore N; Sarnaik S; Hobbs WE; Light DR; Hines P
Br J Haematol; 2016 Sep; 174(6):970-82. PubMed ID: 27291690
[TBL] [Abstract][Full Text] [Related]
11. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
13. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.
de Andrés C; Teijeiro R; Alonso B; Sánchez-Madrid F; Martínez ML; Guzmán de Villoria J; Fernández-Cruz E; Sánchez-Ramón S
PLoS One; 2012; 7(4):e34103. PubMed ID: 22496780
[TBL] [Abstract][Full Text] [Related]
14. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients.
Vuletić A; Jurišić V; Jovanić I; Milovanović Z; Nikolić S; Konjević G
J Surg Res; 2013 Aug; 183(2):860-8. PubMed ID: 23522458
[TBL] [Abstract][Full Text] [Related]
15. A rapid method for assessment of natural killer cell function after multiple receptor crosslinking.
Al-Hubeshy ZB; Coleman A; Nelson M; Goodier MR
J Immunol Methods; 2011 Mar; 366(1-2):52-9. PubMed ID: 21281644
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis.
Frisch ES; Häusler D; Weber MS
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37072216
[TBL] [Abstract][Full Text] [Related]
17. The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients.
Mirjačić Martinović K; Konjević G; Babović N; Inić M
J Surg Res; 2011 Dec; 171(2):637-49. PubMed ID: 20828749
[TBL] [Abstract][Full Text] [Related]
18. Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients.
Mirjačić Martinović K; Babović N; Džodić R; Jurišić V; Matković S; Konjević G
J Transl Med; 2015 Apr; 13():120. PubMed ID: 25889680
[TBL] [Abstract][Full Text] [Related]
19. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
Lakshmikanth T; Burke S; Ali TH; Kimpfler S; Ursini F; Ruggeri L; Capanni M; Umansky V; Paschen A; Sucker A; Pende D; Groh V; Biassoni R; Höglund P; Kato M; Shibuya K; Schadendorf D; Anichini A; Ferrone S; Velardi A; Kärre K; Shibuya A; Carbone E; Colucci F
J Clin Invest; 2009 May; 119(5):1251-63. PubMed ID: 19349689
[TBL] [Abstract][Full Text] [Related]
20. Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas.
Nocturne G; Boudaoud S; Ly B; Pascaud J; Paoletti A; Mariette X
J Autoimmun; 2017 Jun; 80():56-64. PubMed ID: 28214146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
